Results 21 to 30 of about 20,886 (213)

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten

Therapeutic Advances in Chronic Disease, 2022
Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterised by unexplained left ventricular hypertrophy. Left ventricular outflow tract obstruction is an integral component of the disease, often resulting in significant symptoms, but ...
Susan Mathai, Lynne Williams
doaj   +1 more source

Small Molecules to Treat Cardiovascular Disease: Cardiac Myosin Inhibitors

Cardiovascular Innovations and Applications
Lisa D. Wilsbacher
doaj   +2 more sources

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]

Cardiologia Hungarica, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the core molecular defect of the disease, by selectively ...
Pálinkás, Eszter Dalma, Sepp, Róbert, Olivotto, Iacopo   +2 more
openaire   +2 more sources

Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]

Zhongguo quanke yixue
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj   +1 more source

Disruption of calcium homeostasis in cardiomyocytes underlies cardiac structural and functional changes in severe sepsis. [PDF]

PLoS ONE, 2013
Sepsis, a major cause of morbidity/mortality in intensive care units worldwide, is commonly associated with cardiac dysfunction, which worsens the prognosis dramatically for patients.
Mara R N Celes, Lygia M Malvestio, Sylvia O Suadicani, Cibele M Prado, Maria J Figueiredo, Erica C Campos, Ana C S Freitas, David C Spray, Herbert B Tanowitz, João S da Silva, Marcos A Rossi   +10 more
doaj   +1 more source

Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction

Life, 2023
Despite the improvements in the treatment of coronary artery disease (CAD) and acute myocardial infarction (MI) over the past 20 years, ischemic heart disease (IHD) continues to be the most common cause of heart failure (HF). In clinical trials, over 70%
Sabina Andreea Leancă, Irina Afrăsânie, Daniela Crișu, Iulian Theodor Matei, Ștefania Teodora Duca, Alexandru Dan Costache, Viviana Onofrei, Ionuţ Tudorancea, Ovidiu Mitu, Minerva Codruța Bădescu, Lăcrămioara Ionela Șerban, Irina Iuliana Costache   +11 more
doaj   +1 more source

The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review. [PDF]

Heart Fail Rev
Abstract Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular, non-dilated hypertrophy in the absence of another secondary underlying cause. There has been an ongoing increase in the diagnosis of HCM over the past couple of decades, prompting further work in the area of pharmacological and ...
Othman L, Koskina L, Huerta N, Rao SJ.
europepmc   +3 more sources

Hypertrophic Cardiomyopathy in the Era of Targeted Therapy: The Role of Cardiac Myosin Inhibitors, Contemporary Sudden Cardiac Death Risk Stratification, and the Importance of Differential Diagnosis — A Narrative Review

Journal of Education, Health and Sport
Introduction and purpose: Hypertrophic cardiomyopathy (HCM) is a common genetic myocardial disease characterized by unexplained left ventricular hypertrophy, phenotypic heterogeneity, and a clinical course ranging from asymptomatic presentation to heart
Julia Parda, Jakub Bundyra, Dominika Janik, Oliwia Zuzanna Gańska, Agata Sochocka, Zuzanna Zapart, Martyna Szepietowska, Nina Nowicka, Alicja Sikorska, Emil Mian   +9 more
doaj   +1 more source

The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients with Symptomatic Hypertrophic Cardiomyopathy

Translation, 2023
Please view the PDF to see the formatted meeting abstract.  
Mohammand Yassen
doaj   +1 more source

Treatment of obstructive hypertrophic cardiomyopathy: the role of modern imaging and the place of surgery in the era of myosin inhibitors

Zaporožskij Medicinskij Žurnal
Aim. To evaluate modern approaches to preoperative planning of septal myectomy in patients with obstructive hypertrophic cardiomyopathy (HCM), to define the role of multimodality imaging (echocardiography, magnetic resonance imaging (MRI), computed ...
M. O. Tregubova, K. V. Rudenko, M. M. Tkachenko, P. A. Danchenko, A. O. Bei   +4 more
doaj   +1 more source